| First Author | Zhao Y | Year | 2020 |
| Journal | Aging Cell | Pages | e13239 |
| PubMed ID | 32964663 | Mgi Jnum | J:296934 |
| Mgi Id | MGI:6469365 | Doi | 10.1111/acel.13239 |
| Citation | Zhao Y, et al. (2020) Klotho overexpression improves amyloid-beta clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease. Aging Cell :e13239 |
| abstractText | Alzheimer's disease (AD) is the most prevalent type of dementia, characterized by the presence of amyloid-beta (Abeta) plaques. We previously reported that Klotho lowered Abeta levels in the brain and protected against cognitive deficits in amyloid precursor protein/presenilin 1(APP/PS1) mice. However, the underlying mechanism remains unclear. In this study, we induced intracerebral Klotho overexpression in 13-month-old APP/PS1 mice by injecting lentivirus that carried full-length mouse Klotho cDNA in the lateral ventricle of the brain. We examined the effects of Klotho overexpression on cognition, Abeta burden, Abeta-related neuropathology, microglia transformation, and Abeta transport systems in vivo. Additionally, we investigated the effects of Klotho on Abeta transport at the blood-cerebrospinal fluid barrier by knocking down Klotho in primary human choroid plexus epithelial cells (HCPEpiCs). The upregulation of Klotho levels in the brain and serum significantly ameliorated Abeta burden, neuronal and synaptic loss and cognitive deficits in aged APP/PS1 mice. Klotho treatment significantly inhibited NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) and the subsequent transformation of microglia to the M2 type that may enhance microglia-mediated Abeta clearance. Meanwhile, Klotho overexpression also regulated Abeta transporter expression, which may promote Abeta transporter-mediated Abeta clearance. Moreover, the ability of HCPEpiCs to transport Abeta in vitro was also significantly impaired by Klotho knockdown. Given the neuroprotective effect of Klotho overexpression, the present findings suggest that Klotho should be further investigated as a potential therapeutic target for AD. |
